Blue Earth Diagnostics and GE Healthcare (NYSE:GE) said today that the group has inked a deal to establish the manufacturing of Blue Earth Diagnostic’s positron emission tomography imaging product, Axumin, in the U.K.
The agreement with GE Healthcare is part of Blue Earth Diagnostics’ move towards commercializing Axumin since it won marketing authorization from the European Commission in May this year.
Axumin is designed to be used in PET imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated prostate specific antigen levels following primary curative treatment, the company reported.
“This agreement with GE Healthcare marks the first step towards full commercial availability of Axumin in the UK.,” Blue Earth Diagnostics’ CEO Jonathan Allis said in prepared remarks.
“Detection and localization of recurrent prostate cancer is a significant unmet medical need, and Blue Earth Diagnostics is committed to making Axumin accessible to clinicians and their patients across Europe. Today’s announcement is another step towards that goal, and we look forward to working with the team at GE.”
“We are thrilled to support Blue Earth Diagnostics in their mission to improve prostate cancer care for patients in the UK,” Kevin O’Neill, GM of GE Healthcare Life Sciences’ core imaging business, added. “We are very excited to contribute to this project with the expertise, quality and reliability of GE Healthcare’s PET production capabilities in the UK.”